DarioHealth Corp.

NASDAQ:DRIO

Medical - Diagnostics & Research

Healthcare
$5.13 -1.68%

-$0.12 today

Market cap
$50.27M
Beta
1.08
P/E (TTM)
5.5
EPS (TTM)
$1.26
52W Low $5.94High $17.74

Volume 0.01M

Average 0.01M

DRIO Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

DarioHealth Corp.NASDAQ: DRIO

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit declines year over year

Q1 FY2026 gross profit of $3.2M fell 17.6% year over year, ahead of the -35.5% change in trailing-twelve-month gross profit. Sequentially, it rose 35.0% from the prior quarter. Over 3 fiscal years it compounded at +9.5% a year.

Context

  • Gross profit amounted to 56.6% of revenue in FY2025, up 7.6 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -17.6% holds above the trailing-twelve-month pace of -35.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.2M+35.0% QoQ
Last fiscal yearDec 2025
$12.67M-4.5% YoY
LTMMar 2026
$11.98M-35.5% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.6%——
1 year-4.5%——
3-year CAGR+9.5%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
12.67M USD
Year-over-year change
-4.5%
4-year CAGR
+11.9%

Gross Profit vs competitors

How DRIO compares with its peers on the latest reported figures

  • DRIO's LTM Mar 2026 gross profit of $11.98M is the 8th highest of the 11 companies compared; the peer median is $91.68M.
  • Its year-over-year change of -35.5% is the 10th highest of 11, against a peer median of +20.5%.
  • Gross profit amounts to 56.5% of revenue for DRIO, versus a peer median of 58.8%.
DRIO Competitors Peer median
Gross Profit for DRIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MYGNMyriad Genetics, Inc.LTM Mar 2026$580M -0.3%+6.6%70.0%
OFIXOrthofix Medical Inc.LTM Mar 2026$569.63M +5.4%+17.8%69.0%
AVNSAvanos Medical, Inc.LTM Mar 2026$347.6M -7.9%-4.0%48.6%
INNVInnovAge Holding Corp.LTM Mar 2026$196.25M +31.8%+62.9%20.7%
FLGTFulgent Genetics, Inc.LTM Mar 2026$124.02M +9.3%-29.1%38.7%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$59.34M +140.9%+1.1%37.1%
VSTMVerastem, Inc.LTM Mar 2026$41.53M +315.3%+114.5%83.7%
DRIODarioHealth Corp.LTM Mar 2026$11.98M -35.5%+9.5%56.5%
NNNNAnbio Biotechnology Class A Ordinary SharesFY2025$8.51M +44.6%-12.2%87.2%
RGNXREGENXBIO Inc.LTM Mar 2026-$120K -100.1%+37.2%0.1%
ABSIAbsci CorporationLTM Mar 2026-$24.18M +48.7%—1316.9%
Peer median (excluding DRIO) $91.68M+20.5%+6.6%58.8%

Competitors are the stored peer set for DRIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.51M27.66M20.35M27.04M22.36M
Cost of Revenue12.44M18M14.37M13.77M9.69M
Gross Profit8.07M9.66M5.98M13.27M12.67M
Gross Margin39.3%34.9%29.4%49.1%56.6%
Research & Development17.22M19.65M20.25M24.18M13.79M
Selling, General & Admin62.36M46.82M41.8M46.83M35.53M
Operating Expenses84.56M66.47M62.17M71.01M49.32M
Depreciation & Amortization4.46M4.72M4.99M7.43M3.56M
EBITDA(70.02M)(55.6M)(54.38M)(37.08M)(34.69M)
EBITDA Margin-341.3%-201.0%-267.2%-137.1%-155.2%
Operating Income(76.49M)(56.81M)(56.19M)(57.74M)(36.66M)
Operating Margin-372.9%-205.4%-276.1%-213.6%-163.9%
Interest Income44K506K1.87M1.12M943K
Interest Expense84K2.68M645K96K3.36M
Other Income / Expenses(235K)(5.38M)(3.17M)13.15M(4.95M)
Income Before Tax(76.73M)(62.19M)(59.36M)(44.6M)(41.61M)
Pre-Tax Margin-374.1%-224.9%-291.7%-164.9%-186.1%
Income Tax Expense32K4K64K(1.85M)105K
Net Income(76.76M)(62.19M)(59.43M)(42.75M)(41.71M)
Net Margin-374.2%-224.9%-292.0%-158.1%-186.6%
EPS (Basic)(4.63)(2.63)(1.93)(0.74)1.24
EPS (Diluted)(4.63)(2.63)(1.93)(0.74)1.24
Weighted Avg Shares16.59M23.64M28.37M40.42M49.63M
Weighted Avg Shares (Diluted)16.59M23.64M28.37M40.42M49.63M

DarioHealth Corp.

NASDAQ:DRIO

Intrinsic Alpha fair value

Locked

Current Price

$5.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.